Scientists Reprogram Immune Cells In Vivo To Combat Cancer

Scientists at the University of California, San Francisco (UCSF) have pioneered a groundbreaking technique to reprogram immune cells, specifically T cells, directly within a patient's body to target and combat cancer. This innovative approach, detailed in a recent scientific publication, aims to circumvent the complex, time-consuming, and prohibitively expensive process currently required for CAR-T cell therapy. The conventional method involves extracting a patient's T cells, genetically modifying them in a laboratory to express chimeric antigen receptors (CARs) that recognize cancer cells, expanding these engineered cells, and then reinfusing them back into the patient. This ex vivo manufacturing process can take several weeks and incurs substantial costs, often running into hundreds of thousands of dollars per treatment, limiting its accessibility.

The UCSF team's novel in vivo CAR-T cell engineering utilizes a sophisticated two-particle delivery system. One particle carries CRISPR gene-editing tools, a powerful technology for precisely altering DNA sequences. The second particle delivers new DNA sequences designed to equip the T cells with cancer-targeting capabilities. These particles are engineered to specifically target T cells within the body. Upon reaching their target, the CRISPR system facilitates the insertion of the new cancer-targeting DNA into a predetermined location within the T cell's genome. This precise genomic integration is crucial for ensuring the CARs are expressed correctly and function effectively, while also minimizing the risk of off-target edits that could lead to unintended consequences.

This in vivo reprogramming strategy holds significant promise for making CAR-T cell therapy more efficient and accessible. By performing the engineering directly within the patient, the researchers aim to drastically reduce the manufacturing time and associated costs. This could potentially accelerate treatment timelines for patients with various types of cancer, including leukemias and lymphomas, for which CAR-T therapy has shown considerable success. The ability to engineer cells on-demand within the body could also allow for more personalized and adaptive therapeutic strategies, where treatments could be adjusted based on a patient's real-time response. Further research and clinical trials will be necessary to validate the safety and efficacy of this in vivo approach in human patients, but the initial findings represent a significant leap forward in the field of cancer immunotherapy.